Table 3.
Geometric Mean Antibody Titers and Percentage of Participants With a Vaccine Response at 1 Month After Vaccination in the MenACWY-TT and MenACWY-DT Groups (ATP Cohort for Immunogenicity)
| Antibody | GMT (95% CI) |
Adjusted GMT Group Ratio MenACWY-TT lot A or B/MenACWY-DT | Adjusted GMT Group Ratio MenACWY-TT lot A/MenACWY-TT lot B | Vaccine Response |
|||||
|---|---|---|---|---|---|---|---|---|---|
| Group | N | Pre | N | Post | (95% CI) | (95% CI) | N | %a (95% CI) | |
| MenA | MenACWY-TT lot A | 310 | 3.6 (3.1, 4.0) | 315 | 54.2 (43.5, 67.4) | 1.34 (0.97, 1.84) | 1.08 (0.79, 1.47) | 310 | 70.3 (64.9, 75.4) |
| MenACWY-TT lot B | 309 | 3.6 (3.2, 4.1) | 309 | 49.6 (39.6, 62.1) | 1.24 (0.90, 1.73) | – | 300 | 71.3 (65.9, 76.4) | |
| MenACWY-DT | 306 | 3.6 (3.2, 4.1) | 305 | 41.3 (32.3, 52.9) | – | – | 297 | 64.3 (58.6, 69.8) | |
| MenC | MenACWY-TT lot A | 288 | 15.6 (12.3, 19.9) | 307 | 687.1 (510.5, 924.9) | 1.35 (0.92, 1.99) | 0.92 (0.62, 1.38) | 281 | 77.2 (71.9, 82.0) |
| MenACWY-TT lot B | 286 | 16.0 (12.8, 20.0) | 304 | 755.8 (557.3, 1025.0) | 1.47 (1.00, 2.17) | – | 274 | 82.5 (77.5, 86.8) | |
| MenACWY-DT | 289 | 18.0 (14.4, 22.6) | 296 | 543.3 (411.2, 718.0) | – | – | 274 | 76.3 (70.8, 81.2) | |
| MenW-135 | MenACWY-TT lot A | 293 | 7.7 (6.1, 9.7) | 298 | 174.5 (138.6, 219.6) | 1.60 (1.15, 2.23)b | 1.04 (0.76, 1.43) | 279 | 71.0 (65.3, 76.2) |
| MenACWY-TT lot B | 290 | 7.6 (6.0, 9.6) | 292 | 161.6 (128.3, 203.5) | 1.55 (1.11, 2.15) | – | 270 | 72.6 (66.9, 77.8) | |
| MenACWY-DT | 299 | 7.4 (5.9, 9.2) | 297 | 101.7 (77.9, 132.7) | – | – | 289 | 64.0 (58.2, 69.6) | |
| MenY | MenACWY-TT lot A | 296 | 45.7 (35.9, 58.2) | 313 | 349.1 (298.1, 408.8) | 1.54 (1.21, 1.97) | 0.91 (0.73, 1.14) | 293 | 51.2 (45.3, 57.1) |
| MenACWY-TT lot B | 306 | 49.8 (39.1, 63.4) | 307 | 387.4 (329.7, 455.1) | 1.66 (1.30, 2.13) | – | 294 | 51.0 (45.2, 56.9) | |
| MenACWY-DT | 304 | 55.3 (43.7, 69.9) | 305 | 253.8 (204.9, 314.5) | – | – | 295 | 39.0 (33.4, 44.8) | |
Abbreviations: Adjusted GMT, geometric mean antibody titer adjusted for age strata and baseline titer; ATP, according to protocol; CI, confidence interval; GMT, geometric mean antibody titer (reciprocal dilution) calculated on all participants; N, number of subjects with results available; post, postvaccination at month 1; pre, prevaccination at month 0.
aPercentage of participants with a vaccine response.
bBolded text indicates statistically significant group difference in GMT based on exploratory analysis.